Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Oneness submits IND in U.S. for phase II study of FB-704A in severe asthma

Feb. 19, 2021

New ENPP2 inhibitors identified at Boehringer Ingelheim

Feb. 18, 2021

Diffusion completes phase Ib study of TSC in hospitalized COVID-19 patients with hypoxemia

Feb. 17, 2021

Phase III trials of ziritaxestat in IPF discontinued

Feb. 11, 2021

NeuroRx reports preliminary phase IIb/III trial data on Zyesami in COVID-19 respiratory failure

Feb. 10, 2021

ImmunoMet Therapeutics set to begin phase I U.S. study of IM-156 in IPF

Feb. 9, 2021

In vivo data on IHL-675A supports expansion of indications to include COPD and asthma

Feb. 8, 2021

Phase II trial of ensifentrine pMDI formulation in COPD meets lung function endpoints

Feb. 2, 2021

Ampio expands phase I trial of Ampion for COVID-19 respiratory distress based on early data

Feb. 2, 2021

FDA approves IND application for Zofin in COPD

Jan. 29, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...